← Markets

MoonLake Immunotherapeutics

MLTX · NASDAQ

Market closed$19.68$0.670000 (+3.52%)After hours $19.69 · +0.05%

Key statistics

Previous close$19.01
Open$18.78
Day high$19.96
Day low$18.78
52-week high$62.75
52-week low$5.95
Market cap1.63B
Volume719.37K
Average volume1.10M
P/E ratio-5.09
Forward P/E—
EPS-3.87
Dividend yield0.00%

Market context

Why it moved

MLTX shares moved higher likely driven by broader positive sentiment in the biotech and pharmaceutical sector, buoyed by recent FDA approvals and positive clinical trial results across peer companies, attracting investor interest into the space.

StocktwitsStocktwitsFacebookStocktwitsYahoo Finance

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026MoonLake Immunotherapeutics rallied sharply, with shares closing up over 3.5% as investors position ahead of imminent 52-week clinical trial data for sonelokimab in hidradenitis suppurativa (HS) — a key catalyst expected in Q2/Q3 2026. The move comes amid a broader tailwind for biopharma, with UBS upgrading the healthcare sector and citing M&A activity as a key driver; ongoing buyout speculation (Merck previously offered over $3 billion) continues to support sentiment, alongside MoonLake's planned BLA submission for HS in September 2026.

3.5245

July 17, 2026MoonLake Immunotherapeutics fell nearly 5% amid broad healthcare sector weakness, with the XLV ETF under pressure as hospital stocks like UHS and HCA dragged the sector lower on labor cost concerns and insurance coverage headwinds. The decline comes as investors await pivotal near-term catalysts: MoonLake plans to submit its BLA for sonelokimab in hidradenitis suppurativa by end of September 2026, with FDA acceptance and a Priority Review decision expected by November. Buyout speculation around a potential Merck acquisition remains a persistent undercurrent, while analysts maintain a consensus Buy with an average price target near $27.

-4.7595

July 16, 2026MoonLake Immunotherapeutics gained over 2% in regular trading but slipped more than 4% in after-hours as investors continue to weigh imminent late-stage catalysts. With full 52-week data from both Phase 3 hidradenitis suppurativa (HS) trials expected in Q2 and a BLA submission planned for September 2026, the stock has surged 63% year-to-date on pipeline optimism. Persistent M&A speculation—following Merck's reported $3B+ takeover approach in 2025—and a favorable UBS upgrade of the broader biotech sector add to investor interest, even as the stock trades well below analyst consensus targets averaging ~$27.62.

2.2541

July 15, 2026MoonLake Immunotherapeutics closed down ~4.4% amid broader healthcare sector weakness on a day when major sector constituents like Abbott Labs fell sharply and XLV faced pressure ahead of key earnings. Investor focus remains squarely on the upcoming BLA submission for sonelokimab in hidradenitis suppurativa, planned for late September 2026, following a positive FDA meeting in April. With 52-week HS trial data expected soon, psoriatic arthritis readouts on deck, and persistent M&A speculation around Merck as a potential acquirer, analysts maintain a consensus Buy with an average price target of ~$27.62.

-4.3606

July 14, 2026MoonLake Immunotherapeutics closed essentially flat amid a broadly constructive backdrop for biotech stocks, with investors continuing to monitor the company's late-stage sonelokimab pipeline in hidradenitis suppurativa. Sentiment remains supported by an anticipated FDA submission for HS in September 2026, ongoing M&A speculation — Merck has been cited as a potential acquirer since a reported $3B+ approach in 2025 — and Goldman Sachs noting that immunology is a prime area for biopharma dealmaking as the broader biotech sector outpaces tech over the past year.

0.2456

July 11, 2026MoonLake Immunotherapeutics gained, buoyed by the broader biotech sector's emerging leadership role as Jim Cramer and analysts highlight biotech as the market's hottest group, with the XLV hitting record highs. Investor focus remains squarely on sonelokimab's upcoming 52-week HS trial results and a planned FDA filing for hidradenitis suppurativa in September 2026—with a potential Priority Review decision by year-end—while ongoing M&A speculation around a Merck acquisition continues to underpin sentiment. Above-average volume (~82% above the 30-day average) and after-hours gains to $20.76 reflect continued positioning ahead of these near-term catalysts.

2.1576

July 10, 2026MoonLake Immunotherapeutics surged as investors positioned around imminent late-stage trial catalysts and a broader biotech rally, with Jim Cramer calling biotech 'the hottest group in the market' and predicting an M&A flood. Full 52-week data from two pivotal HS trials are expected imminently, alongside primary psoriatic arthritis data due mid-2026 — all ahead of a planned BLA submission in September 2026. Merck acquisition speculation remains alive, with analysts holding a consensus price target of ~$27.62, roughly 46% above recent levels.

4.5097

July 9, 2026MoonLake Immunotherapeutics closed modestly lower amid a broadly volatile session, as broader market risk-off sentiment — driven by Middle East tensions and a chip-led tech selloff — weighed on small-cap biotech names. Despite the slight dip, the stock edged back toward its close in after-hours trading. Investor attention on biotech remains elevated, with Jim Cramer recently calling the sector 'the hottest group in the market' and predicting a wave of M&A deals under the new FDA leadership, which could spotlight mid-cap names like MoonLake with late-stage inflammatory disease assets.

-0.4178

Stock Titan · July 14, 2026MoonLake Immunotherapeutics (NASDAQ: MLTX) raises $30M via option exerciseGlobeNewswire · June 24, 2026MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingSimply Wall Street · June 24, 2026MoonLake Immunotherapeutics (MLTX) On Phase 3 Data While A 6x P B Valuation Looks PriceyMoomoo · June 24, 2026H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45Stocktwits · June 22, 2026MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?Stock Titan · June 21, 2026MoonLake’s HS drug posts 67% HiSCR75 at Week 52Stocktwits · February 18, 2026MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter IgnitesPR Newswire · November 25, 2025MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
Benzinga · July 1, 2026Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29
Mt Newswire · June 24, 2026MoonLake Immunotherapeutics Prices $200 Million Public Offering
Mt Newswire · June 23, 2026Moonlake Immunotherapeutics Insider Sold Shares Worth $862,205, According to a Recent SEC Filing
Mt Newswire · June 22, 2026MoonLake Immunotherapeutics Plans $150 Million Public Offering
Benzinga · June 22, 2026MoonLake Immunotherapeutics Announces Proposed Public Offering Of $150M Of Its Class A Ordinary Shares
Benzinga · June 22, 2026Why Is MoonLake Immunotherapeutics Stock Soaring Monday?
Benzinga · June 22, 2026Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa
Benzinga · June 9, 2026BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target

Peers

S&P 500SPX · $7,457.69-1.01%Amneal Pharmaceuticals, Inc.AMRX · $17.85-1.05%Travere Therapeutics, Inc.TVTX · $56.71+2.59%Oruka Therapeutics, Inc.ORKA · $92.70+11.63%AbCellera Biologics Inc.ABCL · $6.47+4.95%Abivax S.A.ABVX · $136.65-0.81%Agios Pharmaceuticals, Inc.AGIO · $39.61+2.30%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%Xenon Pharmaceuticals Inc.XENE · $68.26+1.91%Erasca, Inc.ERAS · $19.17+0.79%United Community Banks, Inc.UCB · $36.45-1.73%Arcus Biosciences, Inc.RCUS · $27.37+2.74%